Autoreactive immune system

The autoreactive immune system refers to a pathological state characterized by the loss of immunological self-tolerance, where the immune system mistakenly identifies and attacks the body's own constituents (StatPearls, 2023). This condition is the underlying driver of autoimmune diseases, involving the activation of self-reactive T-cells and the production of autoantibodies by B-cells (NIH, 2022). Because it represents a systemic failure of immune regulation rather than a single protein, it is not classified as a discrete therapeutic target in the traditional sense. Instead, drug development focuses on specific molecular components within this system, such as cytokines (e.g., TNF, IL-17) or signaling pathways (e.g., JAK/STAT), to mitigate damage (PubMed, 2021). Common therapeutic strategies include the use of monoclonal antibodies and small molecule inhibitors to suppress these specific inflammatory mediators. However, targeting the autoreactive immune system often results in broad immunosuppression, which can lead to serious safety concerns like increased infection risk. Managing this system is essential for treating chronic conditions like rheumatoid arthritis, lupus, and multiple sclerosis. Ultimately, the goal of therapy is to restore immune homeostasis without compromising the host's ability to defend against pathogens.

Other names

AutoimmunitySelf-reactive immune systemLoss of self-toleranceDysregulated immune system

Immunomodulation and immunosuppression through the inhibition of specific cytokines, depletion of B-cells, or interference with T-cell activation and signaling pathways.